Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.
In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...
Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of ...
Hosted on MSN11mon
4 Ways to Stop a Runny Nose that Actually WorkSteam inhalation can also open up congested nasal passages and ... such as triamcinolone (Nasacort AQ), fluticasone (Flonase), or sprays containing budesonide. An example of an antihistamine spray ...
The phase 3b BATURA study showed Airsupra (albuterol/budesonide) achieved a statistically significant reduction in the risk of severe asthma exacerbations when used as needed for rescue therapy ...
Zacks.com on MSN3d
AstraZeneca Inks Agreement to Boost Cardiovascular PipelineAstraZeneca AZN announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd ...
AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...
AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...
8d
The increasing incidence of respiratory conditions like asthma, COPD, and bronchitis mainly drives the growth of the inhalable drugs market. Additionally, the rising prevalence of diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results